Target identification and intervention strategies against amebiasis

Area of Science:

• Parasitology
• Infectious Diseases
• Microbiology

Background:

• Amebiasis, caused by Entamoeba histolytica, is a significant parasitic disease in developing nations, responsible for substantial mortality.
• While often asymptomatic, E. histolytica can cause severe intestinal and hepatic disease.
• Current treatments, primarily metronidazole (MTZ), face challenges due to potential adverse effects and emerging drug resistance.

Purpose of the Study:

• To review and analyze emerging therapeutic strategies for amebiasis.
• To evaluate novel approaches in light of current understanding of the gut microbiota in amebiasis patients.
• To address the need for alternative treatments against Entamoeba histolytica.

Main Methods:

• Comprehensive literature review of amebiasis treatment strategies.
• Analysis of existing and novel therapeutic approaches, including drug repurposing and natural products.
• Consideration of the role of gut microbiota in amebiasis pathogenesis and treatment.

Main Results:

• Several promising strategies are emerging, including enhanced amebicides, drug repurposing, and vaccination.
• Targeting essential parasite components and utilizing probiotics/natural products show potential.
• The gut microbiota's influence on amebiasis and treatment efficacy is increasingly recognized.

Conclusions:

• The development of new therapeutic strategies is essential to combat amebiasis and overcome metronidazole resistance.
• Integrating knowledge of the gut microbiota may lead to more effective and targeted treatments.
• A multi-pronged approach involving drug development, host-directed therapies, and microbiome modulation is needed.